星源材质主业为锂电隔膜的研发、生产和销售，2016年在A股上市，IPO募资6.5亿，用于锂电隔膜的扩产、还贷和补流。 2025年7月7日，星源材质首次向港交所提交上市申请，以打造国际化的资本运作平台，进一步推动公司国际化业务的发展。 2016年，星源材质在A股上市，2019年和2022年又两次实施定增。几次融资后，星源材质负债率仍大幅走高并显著高于可比公司，有息负债上升尤为明显。 此外，隔膜行业特别是干法隔膜的产能严重过剩，价格大跌，星源材质此次赴港融资继续扩产，或进一步加剧财务负担。 近年来，星源材质营收规模保持增长，但应收账款周转率不断下滑，经营现金流长期低于资本开支，持续失血导致公司资金饥渴症难解。 2024年，星源材质推行股权激励计划，仅将锂电隔膜的销售量作为行权考核条件，公司增收减利的困境或仍将延续。 有息负债急剧飙升负债率显著偏高 行业产能严重过剩融资继续扩产 出品：新浪财经上市公司研究院 作者：昊 近日，星源材质向港交所递表，再度向港股IPO发起冲击。 2019年8月，星源材质实施上市后的首次定增，计划募资20亿，实际募得8.6亿。2022年7月，公司再次实施定增，计划募资60亿，实际募得35亿 ...

Governance Risks - The company has experienced significant executive turnover, with the former chairman sentenced to 18 months in prison for bribery, leading to a change in leadership [2] - Executives, including director Jin Mao, have engaged in concentrated share sell-offs, raising over 16 million yuan, which occurred around the time of the company's profit warning, raising concerns about their confidence in the company's future [1][2] Operational Risks - The company has projected a net loss of 320 million to 390 million yuan for 2025, a shift from profit in the previous year, with non-recurring losses impacting net profit by approximately 16 million yuan [1][2] - Factors contributing to the decline in performance include macroeconomic conditions, industry demand fluctuations, intensified market competition, and challenges in scaling revenue from the WiNEX product [2][3] Future Challenges - The company has outlined a development plan for 2026, focusing on AI integration in WiNEX products, improving delivery efficiency, and establishing an AI medical division, indicating a strategic pivot [3] - However, the effectiveness of these strategies remains uncertain due to ongoing governance issues and market conditions, alongside the need to rebuild trust in governance and investor relations [3][4]

Core Viewpoint - Dier Medical faces significant challenges, including its first annual loss since its listing, due to internal control issues and a declining market environment in the IVD industry [1][2][7] Group 1: Financial Performance - In 2025, Dier Medical's revenue is projected to decline by 60.12% year-on-year to 469 million yuan, with a net profit of -87 million yuan, marking a 145.31% year-on-year decrease [2][4] - The company anticipates a total loss of at least 1 billion yuan in Q4 2025, with no signs of stabilization [4] - The operating cash flow has seen a net outflow of 580 million yuan in the first three quarters of 2025, following a 299 million yuan outflow in 2024 [4] Group 2: Market Environment - The IVD industry is experiencing a downturn, with A-share IVD sector revenues dropping by 14.5% year-on-year to 27.62 billion yuan in the first three quarters of 2025, and net profits down by 26.4% to 4.49 billion yuan [2] - Dier Medical's performance is lagging behind the industry, with its revenue and profit both declining significantly [2] Group 3: Operational Challenges - The company's gross margin for instrument business plummeted from 33.99% in 2023 to 9.68% in the first half of 2025, while reagent gross margin fell from 75.42% to 60.53% [4] - Dier Medical's business structure is heavily weighted towards instruments rather than reagents, which is contrary to the industry norm of "instruments attract customers, reagents generate profit" [4][5] Group 4: Internal Control Issues - The company received a corrective order from the Jilin Securities Regulatory Bureau for improper revenue recognition and inadequate internal controls, leading to an overstatement of revenue by 3.693 million yuan and profit by 716,000 yuan in 2023 [1][7] - The company has reported a significant increase in credit impairment losses and asset impairment losses, totaling over 25.8 million yuan in the first three quarters of 2025 [5] Group 5: Governance and Strategic Challenges - Despite the acquisition by China Resources Group for 1.8 billion yuan, the expected synergies have not materialized, and the company's performance continues to decline [8] - Dier Medical has launched 14 new products in 2025, but faces stiff competition from domestic leaders and foreign brands in high-end markets [9]

Group 1 - The core issue involves a shareholder rights protection application against Singshan Co., accepted by lawyer Liu Yanmei, with ongoing claims being collected [1] - The Sina shareholder rights protection platform has received a total of 308 claims against Singshan Co. and has three professional lawyers available for representation [2] - Compensation eligibility for Singshan Co. includes purchases made between August 12, 2022, and April 26, 2024, with sales or holdings by April 27, 2024, and a second eligibility period from August 12, 2022, to June 27, 2024, with sales or holdings by June 28, 2024 [3] Group 2 - The platform provides multiple entry points for rights protection, including social media and financial news platforms, requiring personal information and stock transaction details for claims [3][4] - Important considerations for filling out the rights protection form include providing clear personal information and a legally valid transaction statement from a securities company [4] - The process involves submitting a rights protection form, which will be reviewed by operational staff, and if approved, a lawyer will take the case within seven days [3][4]

2月13日消息，新浪股民维权平台今日收到曾姓股民针对天际股份（维权）的维权申请，目前该维权咨询已被张云律师接受。新浪股民维权平台 将关注该股民的索赔进程，相关维权持续征集中。 新浪股民维权平台目前有13名专业律师可代理该公司维权，平台目前已收到166件针对天际股份的维权。 天际股份索赔条件 上市后到2026-02-11之间买入股票，且在2026-02-12收盘时卖出或仍持有。 接受律师：刘鹏、陈宇霞、许峰、宋一欣、刘冰华、李鸿杰、张云、 刘彦梅、厉健、徐劲、赵敬国、张海峰、牛彬 如何快速维权？ 平台有多个维权入口，微博关注@新浪证券、微信关注新浪券商基金、访问新浪财经客户端、新浪财经首页都能找到我们！需要您填写个人姓 名、联系方式，选择索赔公司和索赔理由、代理律师，上传股票对账单。提交维权单后，会有运营人员审核对账单，自审核通过后7日内被律师 接单则维权成功，后续会有律师跟您线下对接。 填写维权单注意事项： 1、请填写详细的个人信息 。2、上传至平台的对账单务必清晰，可识别。 3、对账单应包含股票信息，交易时间，交易数量等关键信息。 4、对 账单必须为证券公司出具有法律效力的对账单的JPG格式或者电子对账单形 ...

Group 1 - The blind box concept sector is showing strong performance, with Hanbang High-Tech reaching the daily limit increase [1] - The news highlights the significant interest and momentum in the blind box market, indicating potential investment opportunities [1] - The report was published at 11:00 on February 13, suggesting timely market activity and investor engagement [1]

Core Viewpoint - Shengyi Technology's stock price has experienced fluctuations, with a current decline of 9.68% year-to-date, despite a recent increase of 2.32% over the last five trading days [1]. Company Overview - Shengyi Technology, established on June 27, 1985, and listed on October 28, 1998, is located in Dongguan, Guangdong Province. The company specializes in the design, production, and sales of copper-clad laminates, bonding sheets, printed circuit boards, ceramic electronic components, LCD products, electronic-grade glass cloth, epoxy resin, copper foil, flexible electronic materials, display materials, packaging materials, and insulation materials [1]. - The main revenue sources for Shengyi Technology are copper-clad laminates and bonding sheets (65.96%), printed circuit boards (28.63%), comprehensive utilization of waste resources (3.37%), and other (2.04%) [1]. Financial Performance - For the period from January to September 2025, Shengyi Technology achieved a revenue of 20.614 billion yuan, representing a year-on-year growth of 39.80%. The net profit attributable to the parent company was 2.443 billion yuan, reflecting a year-on-year increase of 78.04% [2]. - Since its A-share listing, Shengyi Technology has distributed a total of 12.911 billion yuan in dividends, with 4.547 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Shengyi Technology was 94,700, an increase of 26.08% compared to the previous period. The average number of circulating shares per person decreased by 19.91% to 25,277 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, holding 118 million shares (a decrease of 48.99 million shares), and several ETFs, with varying changes in their holdings [3].

烽火通信今年以来股价涨32.39%，近5个交易日涨2.96%，近20日涨8.84%，近60日涨86.44%。 今年以来烽火通信已经1次登上龙虎榜，最近一次登上龙虎榜为1月14日，当日龙虎榜净买入-2.83亿 元；买入总计13.66亿元 ，占总成交额比8.19%；卖出总计16.50亿元 ，占总成交额比9.89%。 2月13日，烽火通信盘中下跌2.08%，截至10:05，报42.47元/股，成交14.14亿元，换手率2.56%，总市值 576.81亿元。 资金流向方面，主力资金净流出7106.82万元，特大单买入2.34亿元，占比16.53%，卖出2.23亿元，占比 15.79%；大单买入3.18亿元，占比22.49%，卖出4.00亿元，占比28.25%。 分红方面，烽火通信A股上市后累计派现37.91亿元。近三年，累计派现4.94亿元。 机构持仓方面，截止2025年9月30日，烽火通信十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股2133.05万股，相比上期增加557.16万股。南方中证500ETF（510500）位居第四大流通股 东，持股1110.20万股，相比上期增加53.96万股。易方达智 ...

2月13日，旗滨集团盘中下跌3.32%，截至09:35，报7.28元/股，成交8309.55万元，换手率0.38%，总市 值215.39亿元。 资金流向方面，主力资金净流出579.52万元，特大单买入297.77万元，占比3.58%，卖出895.58万元，占 比10.78%；大单买入971.26万元，占比11.69%，卖出952.96万元，占比11.47%。 旗滨集团所属申万行业为：建筑材料-玻璃玻纤-玻璃制造。所属概念板块包括：BIPV概念、药用玻璃、 低辐射玻璃、光伏玻璃、太阳能（光伏）等。 截至1月31日，旗滨集团股东户数9.40万，较上期减少7.75%；人均流通股31483股，较上期增加8.40%。 2025年1月-9月，旗滨集团实现营业收入117.80亿元，同比增长1.55%；归母净利润9.15亿元，同比增长 30.90%。 分红方面，旗滨集团A股上市后累计派现79.20亿元。近三年，累计派现16.66亿元。 机构持仓方面，截止2025年9月30日，旗滨集团十大流通股东中，景顺长城新能源产业股票A类 （011328）位居第五大流通股东，持股3481.93万股，相比上期增加557.33万股。广发高端制 ...

2月12日，迪普科技涨0.31%，成交额1.36亿元。两融数据显示，当日迪普科技获融资买入额1293.34万 元，融资偿还1435.00万元，融资净买入-141.66万元。截至2月12日，迪普科技融资融券余额合计3.27亿 元。 融资方面，迪普科技当日融资买入1293.34万元。当前融资余额3.26亿元，占流通市值的2.62%，融资余 额超过近一年60%分位水平，处于较高位。 机构持仓方面，截止2025年9月30日，迪普科技十大流通股东中，香港中央结算有限公司位居第九大流 通股东，持股390.87万股，相比上期减少349.02万股。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 资料显示，杭州迪普科技股份有限公司位于浙江省杭州市滨江区月明路595号迪普科技，成立日期2008 年5月28日，上市日期2019年4月12日，公司主营业务涉及从事企业级网络通信产品的研发、生产、销售 以及为用户提供相关专业服务。主营业务收 ...